Simone Biles joins Arcutis’ skin campaign. Quarterly product sales were $143.9 million.

Arcutis Biotherapeutics reported Q3 2026 net product sales of $143.9M, up 45% YoY and 11% QoQ, driven by ZORYVE demand. The company raised 2026 sales guidance to $535M-$545M. Arcutis partnered with Simone Biles for a skin awareness campaign and expects Phase 2 trial results for ZORYVE foam in vitiligo by year-end. Q3 operating cash flow was $18.9M.

Original reporting
Published Nov 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARQT
Bullish
high confidence
Mentioned
$ARQT
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ARQTBullishHigh
01

Why it matters

The earnings beat and guidance raise provide a fresh catalyst for the stock.

02

Market read

Strong quarterly performance and higher guidance may drive ARQT higher in the near term.

03

What to watch

Potential regulatory delays for new ZORYVE indications could temper upside.

Relevance 8/10Novelty 8/10Timing: today, after the 4:30 p.m. ET earnings call

Background

Arcutis Biotherapeutics reported Q3 2026 results and raised full‑year sales guidance.

Company-level read

Ticker impact

$ARQTBullishHigh confidence
Context

Q3 product sales $143.9M (+45% YoY) and full‑year 2026 guidance raised to $535‑$545M.

Expected impact

likely upward as market prices in higher revenue outlook

Evidence & confidence

Revenue growth and raised guidance are fresh primary disclosures that can move the stock.

Market effects

Strengthens outlook for immuno‑dermatology biotech sector.

Positive for US biotech equities.

Limited to biotech investors; no broad market effect.

Counterpoint

If guidance is overly optimistic, the stock could face disappointment on later data.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Commercial‑stage biotech focused on immuno‑dermatology.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.